Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - CHDR to conduct first-in-human phase 1 trial of IMP761 (ASX:IMM)

-- Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the under...read more

INOVIQ Investor Update (ASX:IIQ)

To view the presentation, download the attached PDF.

Immutep - Positive Feedback received from Spanish Medicines Agency (ASX:IMM)

SYDNEY, AUSTRALIA – April 17, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...read more

INOVIQ and Promega sign Global EXO-NET Agreement (ASX:IIQ)

INOVIQ Ltd (ASX:IIQ) (INOVIQ) and Promega Corporation (Promega) are partnering to unlock the commercial potential of exosomes for research, diagnostic and therapeutic applications. This agreement wi...read more

Immutep - First Clinical Data announced from 90mg Dosing of Efti (ASX:IMM)

-- Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well tolerated -- Encouraging initial efficacy in six metastatic breast cancer pati...read more

Immutep - Half Yearly Report and Accounts (ASX:IMM)

To view the report, download the attached PDF.

INOVIQ - Appendix 4D and FY24 Half Year Financial Report (ASX:IIQ)

To view the appendix, download the attached PDF.

INOVIQ detects 19% more breast cancers than leading test (ASX:IIQ)

INOVIQ Limited (ASX:IIQ or INOVIQ) is excited to announce the successful completion of its breast cancer study. In a 2023 clinical validation study (n=483), INOVIQ’s SubB2M/CA15-3 test dete...read more

INOVIQ - Trading Halt (ASX:IIQ)

Description The securities of INOVIQ Ltd (‘IIQ’) will be placed in trading halt at the request of IIQ, pending it releasing an announcement. Unless ASX decides otherwise, the sec...read more

Immutep - Appointment of Non-Executive Director (ASX:IMM)

SYDNEY, AUSTRALIA – 14 February 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nov...read more

INOVIQ - Appendix 4C and Quarterly Activities Report - December 2023 (ASX:IIQ)

“Those who know me from my role as Chairman of PolyNovo (ASX: PNV), know how excited I am to lead a company dedicated to saving lives and improving patient outcomes. We all have family and fri...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

-- Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing PD-L1 (TPS...read more

Immutep Corporate Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - First Patient Dosed in Urothelial Cancer INSIGHT-005 Trial (ASX:IMM)

SYDNEY, AUSTRALIA – 04 January 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...read more

Immutep - Change of Registered Office Address (ASX:IMM)

SYDNEY, AUSTRALIA – 22 December 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), advises that its registered office and principal plac...read more

Viewing: 1 - 15 of 200 Previous | Next